{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/prescribing-information/calcium-channel-blockers/","result":{"pageContext":{"chapter":{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers","depth":2,"htmlHeader":"<!-- begin field 7194a568-53a0-41bf-8a64-331e82ee097d --><h2>Calcium-channel blockers</h2><!-- end field 7194a568-53a0-41bf-8a64-331e82ee097d -->","summary":"","htmlStringContent":"<!-- begin item 903b6c0b-eac9-478f-846a-3dd5777baab3 --><!-- end item 903b6c0b-eac9-478f-846a-3dd5777baab3 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ba8e2025-0a0b-5119-a504-dd61df744a56","slug":"choice-of-calcium-channel-blocker","fullItemName":"Choice of calcium channel blocker","depth":3,"htmlHeader":"<!-- begin field 6d7fafe1-608f-4a60-a58e-7b3c24b14cc8 --><h3>Choice of calcium channel blocker</h3><!-- end field 6d7fafe1-608f-4a60-a58e-7b3c24b14cc8 -->","summary":"","htmlStringContent":"<!-- begin item 4c0067d5-934a-41c3-9e04-464aa8ed5b95 --><!-- begin field 645e199f-5e3c-4b2b-a787-ad37b0732310 --><ul><li><strong>Monotherapy (when a beta-blocker is contraindicated or not tolerated).</strong><ul><li>A rate-limiting calcium-channel blocker (CCB) (such as diltiazem or verapamil) is preferred to a dihydropyridine CCB. <ul><li>Rate-limiting CCBs, such as verapamil and diltiazem, have the additional action of decreasing myocardial contractility and heart rate.</li><li>Dihydropyridine CCBs can sometimes cause reflex tachycardia, which may increase angina symptoms, although this is more likely to be a problem with short-acting dihydropyridines than with longer-acting preparations.</li></ul></li><li>The different classes of CCB are equally efficacious, so the choice of CCB should be based on the person's preference, comorbidities, potential drug interactions, and adverse effects.</li></ul></li><li><strong>Combination therapy</strong><ul><li>For people taking a beta-blocker, prescribe a dihydropyridine CCB (such as amlodipine, felodipine, or modified-release nifedipine).</li><li>For people not taking a beta-blocker, a rate-limiting CCB may be preferred.</li></ul></li><li><strong>If the person has concomitant heart failure </strong>— prescribe amlodipine or felodipine.</li></ul><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Stable angina: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of stable angina</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">SIGN, 2007</a>], the European Society of Cardiology guideline <em>Management of stable coronary artery disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ESC, 2013</a>] and the American College of Cardiology Foundation (ACCF) <em>Guideline for the diagnosis and management of patients with stable ischemic heart disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ACCF, 2012</a>], and a meta-analysis of 60 randomized controlled trials [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Stason et al, 1999</a>]</p><h4>Nifedipine</h4><ul><li>There is conflicting evidence on the safety of nifedipine in people with angina.<ul><li>A meta-analysis suggests that nifedipine monotherapy or short-acting nifedipine in combination with other drugs for angina may increase the risk of cardiovascular events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Stason et al, 1999</a>].</li><li>However, long-acting nifedipine is safe and reduces the need for coronary angiography and cardiovascular interventions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ESC, 2013</a>].</li></ul></li></ul><!-- end field 645e199f-5e3c-4b2b-a787-ad37b0732310 --><!-- end item 4c0067d5-934a-41c3-9e04-464aa8ed5b95 -->","subChapters":[]},{"id":"b4544281-f97c-5b34-9ea2-4a209cbad153","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 40806532-0395-48a2-b9ff-aec349a2143b --><h3>Cautions and contraindications</h3><!-- end field 40806532-0395-48a2-b9ff-aec349a2143b -->","summary":"","htmlStringContent":"<!-- begin item 5833a348-1e74-4c3c-bba7-e82c12152434 --><!-- begin field 52f2d7d9-8515-4a98-a3ae-e2da5f7660f3 --><ul><li><strong>Rate-limiting calcium-channel blockers (CCBs) (such as verapamil and diltiazem) are contraindicated in people with</strong>:<ul><li>Atrial flutter or fibrillation associated with accessory conducting pathways (for example, Wolff-Parkinson-White-syndrome).</li><li>Heart failure, or history of heart failure.</li><li>Severe bradycardia</li><li>Second- or third-degree heart block (in the absence of a permanent pacemaker).</li><li>Sick sinus syndrome.</li><li>Cardiac outflow obstruction (significant aortic stenosis or obstructive hypertrophic cardiomyopathy) — vasodilatation may result in reduced cardiac output.</li></ul></li><li><strong>Dihydropyridine CCBs (such as amlodipine and felodipine), are contraindicated in people</strong>: <ul><li>With uncontrolled heart failure.</li><li>Severe hypotension.</li><li>Cardiac outflow obstruction (for example high grade aortic stenosis).</li></ul></li><li><strong>Prescribe rate-limiting CCBs with caution to people:</strong><ul><li>With hepatic impairment — dose adjustments may be necessary.</li><li>With myasthenia gravis.</li><li>At risk of developing an intestinal obstruction — calcium channel blockers have an inhibitory effect on intestinal motility.</li></ul></li><li><strong>Prescribe dihydropyridine CCBs with caution to people with:</strong><ul><li>Heart failure.</li><li>A predisposition to tachycardia.</li><li>Hepatic impairment — the initial dose may need to be reduced. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]</p><!-- end field 52f2d7d9-8515-4a98-a3ae-e2da5f7660f3 --><!-- end item 5833a348-1e74-4c3c-bba7-e82c12152434 -->","subChapters":[]},{"id":"30ca3686-b0b7-5bb4-96ef-89e44dbad22b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e7930ce6-0774-48cd-bcfd-8baf90d62256 --><h3>Adverse effects</h3><!-- end field e7930ce6-0774-48cd-bcfd-8baf90d62256 -->","summary":"","htmlStringContent":"<!-- begin item f515f81f-d9d6-4ef3-ba31-301baa26bb49 --><!-- begin field f85bd49c-b5b6-444c-821d-477f78fc3d31 --><ul><li><strong>Vasodilatory adverse effects </strong>(facial flushing, headaches, postural hypotension, and ankle swelling) — these are more common with dihydropyridine calcium-channel blockers (CCBs) than rate-limiting CCBs.<ul><li>Vasodilatory effects usually reduce in severity with continued treatment, although ankle swelling often persists.</li></ul></li><li><strong>Other adverse effects include: </strong><ul><li>Dizziness (common).</li><li>Gastrointestinal disorders, for example constipation, nausea, and dyspepsia (common).</li><li>Atrioventricular block, palpitations (common with diltiazem). </li><li>Malaise, and fatigue (uncommon, but common with diltiazem).</li><li>Myalgia, and arthralgia (uncommon).</li><li>Erythema multiforme (rare).</li><li>Acute renal failure secondary to decreased renal perfusion has been reported in patients taking diltiazem who have reduced left ventricular function, severe bradycardia, or severe hypotension.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Fox et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2020a</a>]</p><!-- end field f85bd49c-b5b6-444c-821d-477f78fc3d31 --><!-- end item f515f81f-d9d6-4ef3-ba31-301baa26bb49 -->","subChapters":[]},{"id":"e7959bc5-7d9f-5435-ab95-b8c7f591f21a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 21d010fc-b4fe-4777-a27a-9eeea6e3b968 --><h3>Drug interactions</h3><!-- end field 21d010fc-b4fe-4777-a27a-9eeea6e3b968 -->","summary":"","htmlStringContent":"<!-- begin item 4e8e14e1-4a89-48ee-8b49-fdab2a6f1812 --><!-- begin field eda60fd9-06c6-4690-859b-fab732066da7 --><ul><li><strong>Antiarrhythmics </strong>—<strong> </strong>there is an increased risk of bradycardia, AV block, and myocardial depression when the rate-limiting calcium-channel blockers (CCBs), diltiazem and verapamil, are prescribed concomitantly with the antiarrhythmic drugs amiodarone and dronedarone.</li><li><strong>Anticoagulants</strong> — verapamil can increase plasma concentrations of dabigatran. Dose adjustments of dabigatran may be necessary.</li><li><strong>Antifungals</strong> (itraconazole and ketoconazole) — metabolism of amlodipine and felodipine is inhibited. Avoid concomitant use. </li><li><strong>Antiretrovirals</strong> (ritonavir) — plasma levels of amlodipine. Dose of amlodipine may need to be reduced. </li><li><strong>Anticonvulsants</strong> (carbamazepine) — verapamil and diltiazem may increase carbamazepine plasma levels. The dose carbamazepine may need to be adjusted.  </li><li><strong>Beta-blockers </strong>— verapamil should not be prescribed with a beta-blocker, as bradycardia, asystole, severe hypotension, and heart failure can occur.<ul><li>A beta-blocker and diltiazem should only be prescribed on specialist advice.</li></ul></li><li><strong>Immunosuppressants </strong>(ciclosporin) —<strong> </strong>verapamil and diltiazem may increase levels of ciclosporin. The dose of ciclosporin may need to be reduced, and renal function monitored. </li><li><strong>Digoxin </strong>—<strong> </strong>diltiazem and verapamil may increase the plasma concentration of digoxin. Dose reductions of digoxin may be necessary</li><li><strong>Grapefruit </strong>— grapefruit (and grapefruit juice) may inhibit the metabolism of CCBs, resulting in increased plasma concentrations that could be clinically important. </li><li><strong>Ivabradine</strong> — concomitant use of ivabradine with verapamil or diltiazem is contraindicated due to the additional heart rate lowering effect.</li><li><strong>Macrolide antibiotics </strong>— the metabolism of CCBs can be reduced by the macrolide antibiotics clarithromycin or erythromycin, leading to an increased risk of adverse effects.</li><li><strong>Statins </strong>—<strong> </strong>increases in statin plasma levels have been noted with atorvastatin, lovastatin or simvastatin when given with diltiazem or verapamil. Fluvastatin, pravastatin, and rosuvastatin are not significantly metabolised by CYP3A4 and are less likely to interact.<ul><li>In a person already taking simvastatin, atorvastatin, or lovastatin, consider reducing the dose of the statin if verapamil or diltiazem are started.</li><li>In a person already taking verapamil or diltiazem, treatment with simvastatin, atorvastatin, or lovastatin should be started at a low dose and gradually titrated up.</li></ul></li><li><strong>mTOR inhibitors (sirolimus, temsirolimus, everolimus)</strong> — amlodipine is a weak CYP3A inhibitor, concomitant use with these drugs may increase their levels.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2018</a>] </p><!-- end field eda60fd9-06c6-4690-859b-fab732066da7 --><!-- end item 4e8e14e1-4a89-48ee-8b49-fdab2a6f1812 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}